Most major histocompatibility complex (MHC) class I proteins have strict requirements for the lengths of peptide ligands that can be bound with high affinity, typically eight to ten residues; there fore, peptides destined for presentation by MHC class I molecules must be precisely cleaved before loading 1 . Proteasomal degrada tion and cytosolic aminopeptidase processing are sufficient for the generation of some class I MHC antigens, but many epitopes require an additional processing step in the endoplasmic reti culum (ER) after transporter associated with antigen processing (TAP)mediated transport 2,3 . A search for peptidases responsible for that activity identified an ERresident, interferonγ-inducible, metalloaminopeptidase that was termed ERassociated amino peptidase 1 (ERAP1) or ER aminopeptidase associated with antigen processing (ERAAP) 4, 5 .
a r t i c l e s
Most major histocompatibility complex (MHC) class I proteins have strict requirements for the lengths of peptide ligands that can be bound with high affinity, typically eight to ten residues; there fore, peptides destined for presentation by MHC class I molecules must be precisely cleaved before loading 1 . Proteasomal degrada tion and cytosolic aminopeptidase processing are sufficient for the generation of some class I MHC antigens, but many epitopes require an additional processing step in the endoplasmic reti culum (ER) after transporter associated with antigen processing (TAP)mediated transport 2, 3 . A search for peptidases responsible for that activity identified an ERresident, interferonγ-inducible, metalloaminopeptidase that was termed ERassociated amino peptidase 1 (ERAP1) or ER aminopeptidase associated with antigen processing (ERAAP) 4, 5 .
Studies of ERAP1deficient cells have shown that ERAP1 gener ates many presented peptide epitopes from larger precursors, but it can destroy other epitopes by trimming them below the mini mal size needed for MHC class I binding 6 . The peptide repertoire carried by MHC molecules of wildtype and ERAP1deficient mice differ substantially 7 . Epitope immunodominance hierarchies dif fer in wildtype and ERAP1deficient mice infected with LCMV 8 , and Tcell responses against many model antigens were reduced in ERAP1deficient mice 9 . Furthermore, crosspresentation of cell associated epitopes was lower in ERAP1deficient mice 10 . ERAP1 dependent epitopes were shown to be important in resistance to Toxoplasma gondii 11 .
Allelic variants of ERAP1 have been linked to a number of human diseases, including the autoimmune disease ankylosing spondylitis (reviewed in ref. 12 ), diabetes 13 , some forms of cervical cancer 14 and hypertension 15 .
An important aspect of ERAP1's specificity that is related to its biological function is its ability to cleave long substrates, in contrast to other aminopeptidases that generally are restricted to substrates shorter than four residues 16 . ERAP1's length specificity is character ized by a sharp increase in activity near eight to ten residues, with peptides up to ~16 residues being processed efficiently 6, 16 . This activ ity matches ERAP1's role in processing antigenic peptide precursors. Proteasomal processing generates peptides of 2-25 residues 17 , with Cterminal residues that generally match MHC class I sequence requirements. The TAP1-TAP2 complex the transporter associated with antigen processing that brings class I and class II antigen precur sors into the ER, prefers peptides of at least 8 residues [18] [19] [20] and up to 16 residues long 20 . Many transported peptides thus require additional trimming to fit into MHC class I binding sites, and processing by ER aminopeptidases may be the final contributor to size selection of antigenic peptides. How ERAP1 fulfills this role is controversial; in addition to ERAP1's intrinsic length dependence 16 , it has been proposed that direct processing of antigenic precursors by ERAP1 while they are partially bound onto MHC class I (ref. 21, 22) , as well as MHCprotection of peptide products released from ERAP1 (ref. 23) , may also contribute to the final repertoire of peptides loaded onto MHC class I. a r t i c l e s ERAP1 has sequence as well as length preferences. ERAP1 was originally identified as a leucinespecific aminopeptidase based on studies with single amino acid fluorogenic substrates 24 , although a wide variety of amino acids can be cleaved. The in vitro activity of ERAP1 toward peptides with various Nterminal residues that has been characterized generally parallels findings from singleresidue model substrates, although with substantially broader overall reac tivity, so that some Nterminal residues are processed efficiently in the context of longer peptides but not as singleresidue sub strates 3, 16, [25] [26] [27] . An in vivo study of ERAP1mediated generation of Tcell epitopes from longer antigenic precursors combined with a statistical analysis of residues preceding naturally processed epitopes in large epitope databases revealed that epitope Nterminal specificity matches ERAP1's peptide specificity measured in vitro 26 . Finally, in addition to its Nterminal specificity, ERAP1 is unusual in showing some preferences regarding the substrate's Cterminal residue 16 and internal sequence 25 .
To clarify the structural basis for ERAP1 specificity and to evalu ate possible models for its length dependence, we determined the 3.0 Å crystal structure of human ERAP1 bound to the aminopepti dase inhibitor bestatin by Xray diffraction. The structure reveals an open conformation with a large interior compartment. A shallow groove extending from the active site potentially can accommodate long peptides by forming a series of electrostatic and hydrophobic interactions consistent with previously reported substrate preferences. Experimental characterization of ERAP1's sensitivity to allosteric acti vation and inhibition by peptides, and comparison with the active site geometries of other M1family members, suggest a mechanism for the lengthdependent hydrolytic activity and allow us to propose a molecular model of how ERAP1 trims antigenic peptide precursors.
RESULTS

Overall structure of ERAP1
ERAP1 is a member of the M1 family of zinc metallopeptidases characterized by GAMEN and HExxHx 18 E sequence motifs. The family includes a wide variety of soluble and membraneassociated aminopeptidases with various specificities and biological functions 28 . Sequences of the five M1family aminopeptidases for which crystal structures have been determined are aligned in Supplementary  Table 1 . These structures reveal increasingly extensive elaborations of a thermolysinlike fold. Sequence homology is strongest in the catalytic domain containing the GAMEN and HExxHx 18 E motifs, weaker in the Nterminal portion and essentially absent in the highly variable Cterminal helical region (Supplementary Table 1 ).
The crystal structure of fulllength recombinant human ERAP1 bound to the aminopeptidase inhibitor bestatin was determined by Xray crystallography using cryogenic diffraction data extending to 3.0 Å ( Table 1) . The structure was solved by molecular replace ment using LTA4H and TIFF3 as search models, with initial phasing using noncrystallographic symmetry relationships among the three copies of ERAP1 observed in the crystallographic asymmetric unit (see Online Methods). The interactions between the three molecules ( Supplementary Fig. 1 ) might provide a model for ERAP1's inter action with ERAP2 (ref. 27) .
The crystal structure of ERAP1 reveals four protein domains, with a large cavity between domains II and IV (Fig. 1a) . As with other M1family members, domain II (green in Fig. 1a) is the catalytic domain that carries the zinc atom, GAMEN and HExxHx 18 E motifs on a thermolysinlike αβ fold. Domain I (blue) is an all-βsandwich domain that docks on top of the thermolysin domain, capping off the active site and providing binding sites for the N terminus of a substrate peptide. Domain III (orange) is a small βsandwich domain between domains II and IV. Among M1family aminopeptidases, domain IV (magenta) is the most variable, ranging from a tightly closed spiral of ten helices in LTA4H to 17 helices in ePepN (Fig. 1a,b) . In ERAP1, domain IV is composed of 16 variously sized helices arranged as eight antiparallel armadillo or HEATtype helixturn helix repeats 29 , assembled side to side to form a concave surface facing toward the active site (Fig. 1c) . Overall, the helices of the Cterminal helical domain are arranged in a large cone or bowl adjacent to the active site, lined by the lateral faces of the evennumbered helices.
The structure of ERAP1 reported here is more open than for other M1family members because of the orientation of its Cterminal helical domain relative to the remainder of the protein (Fig. 1b) . In LTA4H and ColAP, the small Cterminal helical domain packs closely against the catalytic domain, with no intervening small βsandwich domain and no extensive cavity formed. For ePepN and PfAM1, the helical domain is relatively large and similar in overall dimensions to that of ERAP1; however, it packs closely against the active site, forming a closed substratebinding cavity. TIFF3 has a more open domain arrangement somewhat similar to that of ERAP1 but with the Cterminal domain packing closer to the catalytic domain, forming a smaller cavity. In the structure of ERAP1, domain IV extends away from the active site, forming a cavity substantially larger than in the other structures.
Among the three copies of ERAP1 in the crystallographic asym metric unit, the interdomain orientations vary with the differ ences that mostly affect the orientation of domain IV relative to the other domains. Supplementary Fig. 2a shows these three copies after superposition of domain III, revealing a small motion tend ing toward a more 'closed' conformation. A normal mode analysis 30 ( Supplementary Fig. 2b, Supplementary Movie 1) , indicates that further closing motions along the same trajectory are accessible, An unusual feature of the structure is the deep cavity between domains II and IV. This cavity is the largest seen to date for an amino peptidase and potentially can provide easy access to the catalytic site for even the longest of the enzyme's substrates. The cavity (Fig. 1d) , which extends up to 36 Å from the active site to the interior surface of domain IV, probably represents a binding site for long peptide substrates.
Catalytic site
The ERAP1 active site is formed at the junction of five secondary structure elements: helix H2 and the adjacent antiparallel helix H3 that carry the HExxH and E residues of the HExxHx 18 E motif, the GAMEN loop, the domain 1 loop, and helix H5 adjacent to the domain IIdomain IV interface (Fig. 2a) . Bestatin, an αhydroxy-βamino dipeptide analog that functions as a broadspectrum aminopeptidase inhibitor, binds to the active site of ERAP1 by means of a bidentate interaction between its 2hydroxy and amido oxygen atoms and the ERAP1 catalytic zinc atom. The catalytic zinc atom is coordinated by the side chains of His353 and His357 of the HExxH helix and Glu376 of the adjacent helix, with Glu354 next to bestatin's αhydroxyl group (Fig. 2b) . The bestatin N terminus is bound by Glu183 of the domain 1 loop and Glu320 of the GAMEN motif. These interactions are likely to simulate the complex of ERAP1, substrate amide and water molecule that is positioned to attack the peptide's scissile bond. In addition, the main chain of GAMEN residues Gly317 and Ala318 interact with bestatin's carboxylate and amide bond, respectively. The Met319 side chain forms part of the S1 pocket, and the Glu320 side chain carboxy late interacts with bestatin's free N terminus (Fig. 2b) . Asn321, the last of the GAMEN residues, forms hydrogen bonds with the neighbor ing strand that appear to stabilize the local loop conformation (not shown). These interactions are likely to simulate the interaction of ERAP1 with the first few residues of a bound peptide substrate.
Structural alignment of the active sites of other M1 aminopepti dases reveals constellations of conserved catalytic residues that are essentially identical to those of ERAP1, with the exception of Tyr438 (Fig. 2c) . This tyrosine is conserved in all M1family aminopepti dases 28 and has been shown to play an important catalytic role in stabilizing the tetrahedral intermediate formed by water addition to the substrate scissile peptide bond 31 . In the other M1 structures, the analog of Tyr438 is oriented toward the active site in a position such that its hydroxyl can stabilize the tetrahedral intermediate formed by the attack of water at the peptide scissile bond 31, 32 . In the structure of the ERAP1-bestatin complex, Tyr438 is positioned near the active site but is oriented such that its hydroxyl group is more than 8 Å away from bestatin's amide bond, as a result of reorientation of the inter facial helix and adoption of a different rotameric form than found in the other M1aminopeptidase structures (Fig. 2c) . Nonetheless, the sidechain hydroxyl of Tyr438 is essential for catalysis, as tyrosineto phenylalanine substitution at this position causes a 99.5% reduction in catalytic rate (Fig. 2d) .
ERAP1 is unusual among aminopeptidases in its ability to accept large peptide substrates of up to ~16 residues. Optimal activity is observed for peptides of ~10 residues, whereas most peptides of eight or fewer residues are not processed as efficiently 16 . As described above, ERAP1 has a large cavity that provides a potential binding site for such large peptides, formed at the interface between the concave surface of domain II that carries the active site and the concave surface of the domain IV helical bowl. A closer view of the cavity in the vicinity of the active site is shown in Figure 2e . The cavity is relatively narrow near the active site (top left in Fig. 2e ) and widens as it enters domain IV. The wider part of the cavity can accommodate the Cterminal por tion of polypeptide substrates bound with their Nterminal regions in position to be processed at the active site. Because of the sequestered nature of the active site in domain II and the arrangements of domains I and IV around the mouth of the cavity, it is unlikely that ERAP1 can complete the processing of an epitope peptide precursor while it is bound to MHC class I, as previously suggested 21, 22 . Docking experi ments show that the closest possible approach of the N terminus of a peptide bound to an MHC class I protein to the zinc center in ERAP1 is 20 Å, indicating that more than six residues of extended polypeptide would need to protrude from the MHC binding site for ERAP1 to trim a preformed MHC-peptide complex. 
a r t i c l e s
Substrate specificity
The orientation of bestatin in the aminopeptidase active site can help to identify subsites in the active site region that can accommodate peptide side chains [33] [34] [35] [36] . Two possible configurations for long peptides bound to ERAP1 are indicated in Figure 2e . The heads of the arrows are located ~27 Å from the zinc atom, corresponding approximately to the length of an extended seven to eightresidue peptide. Following the convention for naming peptidase sites, we call the site responsible for accommodating the peptide side chain Nterminal to the cleavage site S1 and call subsequent positions S1′, S2′, and so on. Bestatin's phenyl group binds into the aminopeptidase S1 site, with its isobutyl group oriented toward the S1′ site (Fig. 2b,e) . In ERAP1, the S1 site is a relatively shallow hydrophobic pocket lined by the side chains of Ser316 and Met319 of the GAMEN loop, and Gln181 and Glu183 of the D1 loop (Fig. 2b) . Modeling indicates that a leucine or methionine would fit closely into the S1 pocket as the first residue of a bound pep tide. Larger residues such as tryptophan and arginine can make similar contacts but only by adopting rotamers that orient the side chain out of the pocket. Smaller residues can be accommodated but would leave voids within the site. This pattern matches the Nterminal specifi city observed in peptide hydrolysis and antigen presentation studies, in that peptides with Nterminal leucine and methionine residues were processed most efficiently, whereas those with Nterminal tryp tophan, arginine and cysteine were processed less efficiently 3, 16, [25] [26] [27] . The broader reactivity toward peptides as compared to singleresidue substrates likely reflects the contribution of binding sites for peptide side chains beyond S1′ (see below), which can compensate for non optimal interactions in the sterically rather permissive S1′ pocket.
ERAP2, another ER aminopeptidase also involved in ER antigen processing 27, 37 , has a different specificity from ERAP1, with greatly increased preference for fluorogenic amino acid substrates 16, 38 and peptides 27 carrying Nterminal arginine and lysine groups. One difference between ERAP1 and ERAP2 in the S1 pocket region is at position 181, which is glutamine in ERAP1 but aspartate in ERAP2. Residue 181 forms the top of the S1 pocket (Fig. 2b) , and the glutaminetoaspartate substitution would have the effect of length ening the pocket and making it more acidic. A sitespecific mutant of ERAP1 carrying an E181D substitution alters its specificity from hydrophobic toward basic amino acids 39 .
ERAP1 has been shown to be unable to trim peptides with a pro line residue as a second amino acid 3, 26 . The location of the S1′ site in ERAP1 can be estimated using bestatin as a guide (Fig. 2b,e) . Modeling of a mock peptide substrate with proline at the second position indi cates that the side chain cannot be accommodated by the expected S1′ site of ERAP1 without disrupting the GAMEN loop and arrangement of catalytic residues above the nitrogen of the scissile peptide bond.
ERAP1 shows sequence specificity for other regions of the substrate beyond its N terminus, as shown by alaninescanning and library screening studies 25 . Without knowing the structure of ERAP1 bound to a peptide substrate, identification of the sites responsible for this sequence specificity is speculative. However, several aspects of the internal cavity are consistent with it being a binding site for long peptide substrates. Figure 2f shows a top view of ERAP1, represented as an electrostatic potential surface. Dashed lines show approximate distances of 20 Å and 30 Å from the zinc atom in the active site. The overall negative charge of the cavity in this region is consistent with the observed specificity for positively charged residues at several sites in a nineresidue peptide substrate 25 . Shallow pockets within the overall substrate binding cavity, visible as depressions along the sides of the groove shown in Figure 2e , potentially correspond to pockets for peptide side chains, and they could be responsible for ERAP1's observed preferences for hydrophobic residues at internal positions as well as the Cterminal position of nonamer 25 and decamer pep tides 16 . Other binding sites for peptide side chains may be present on the interior faces of helices lining the cavity, as observed for other proteins carrying armadillo and HEAT repeat motifs 40 . a r t i c l e s
Comparison with structure of ERAP1 in the closed conformation During the preparation of this manuscript, a crystal structure of ERAP1 without bestatin was independently determined by another group 41 (Fig. 3) . That structure reveals ERAP1 in a closed conforma tion similar to that observed for LTA4H, ColAP, ePepN and PfAM1, with the Cterminal domain packed closely to the catalytic domain (Fig. 3e) . By aligning the open structure of ERAP1 bound to besta tin (PDB 3MDJ reported here), the closed structure of ERAP1 alone (PDB 2XDT) and the closed structures of LTA4H and ePepN bound to bestatin (PDB 3FUH and 2HPT, respectively) and to tripeptide substrates or substrate analogs (PDB 3B7T and 2ZXG) 32, 33, 35, 36 , we were able to model a polyalanine tripeptide into the ERAP1 active site and evaluate the effect of the opentoclosed conformational change on peptide substrate interactions (Fig. 3b,f) . In the closed conformation, the substrate binding pocket is still large enough to accommodate a 12-14residue peptide, but it is no longer accessible from the exterior of the protein (Fig. 3c,g ), having been closed off by the motion of helices 18-24 in the Cterminal domain (Fig. 3a,b,e,f) .
In the closed conformation, Tyr438 orients toward the active site as in the other M1 aminopeptidases, with the phenolic hydroxyl moving >5 Å to allow for participation in peptidebond hydrolysis (Fig. 3b,f) .
With the exception of Tyr438 on helix H5 and a slight motion of the GAMEN loop, there is no substantial change in any of the active site residues between the open and closed structures. However, residues 417-433, which in the open structure are disordered, fold to extend the H5 helix toward H4 by several turns (Fig. 3b,f) , capping off the top of the S1 site and substantially restricting its solvent accessibility in the closed structure (Fig. 3d,h) . H5′, the extended portion of helix H5, contacts the loop between helices H21 and H22 of the Cterminal domain (Fig. 3f) , providing a possible route for peptideinduced conformational changes in the large Cterminal binding cavity to be communicated to the vicinity of the active site.
Together the two structures of ERAP1 (Fig. 3a,e) provide clear evidence of a large conformational change that is associated with opening of the substrate binding site and is coupled to active site reorganization, as previously suggested for other M1family mem bers 32 . ERAP1 is thus the first M1 aminopeptidase for which struc tures are available in both open and closed conformations, and it is likely to serve as a prototype for understanding regulation of enzyme activity in this entire class of aminopeptidases.
Length-dependent trimming and subsite activation ERAP1 processes peptides that are longer than eight or nine residues much more efficiently than shorter peptides (Fig. 4 and ref. 16 ). This activity is unusual among aminopeptidases, which typically are most active in processing shorter peptides 16 , but it is consistent with ERAP1's role in antigen processing. One potential mechanism for this effect would be that the enzyme's activity is regulated depending on the length of bound peptide substrate. To investigate this possibility, 
a r t i c l e s
we used a small fluorogenic substrate, leucine7amido4methyl coumarin (LAMC), to monitor ERAP1's hydrolytic activity in the presence of peptides of varying lengths (Fig. 4c,d ). We used a series of peptides based on the antigenic peptide SIINFEKL, which previ ously has been used to characterize ERAP1 activity in vitro 6, 16 and in vivo 26 . ERAP1's aminopeptidase activity on LAMC was increased severalfold in the presence of variants of increasing length from four (FEKL) up to eight (SIINFEKL) residues (Fig. 4c, closed bars) over the basal LAMC hydrolysis rate (Fig. 4c, open bar) . These activating pep tides themselves were not long enough to be processed efficiently by ERAP1, as shown in a separate assay (Fig. 4a) . Activation of LAMC hydrolysis decreased with increasing peptide length for variants of 11 residues (QLESIINFEKL) or longer (Fig. 4c) , which, however, were processed efficiently by ERAP1 (Fig. 4a) . A similar pattern of activa tion occurred with a different series of peptides carrying a polyglycine motif, LG n L, of increasing length (Fig. 4d) . The optimum length for activation of LAMC hydrolysis in this series was eight residues. As with the SIINFEKL series, this was shorter than the length needed for efficient hydrolysis of the peptides themselves ( Fig. 4b) (a more detailed analysis of this activity will be presented elsewhere). Shorter peptides not themselves hydrolyzed by ERAP1 can thus act as acti vators for the hydrolysis of LAMC, presumably by converting the enzyme to a more active form upon binding. We investigated the hydrolysis reaction further using steadystate kinetics. To follow hydrolysis of a fulllength peptide, we used the internally quenched decapeptide substrate, WRVYEKC dnp ALK 42 . This peptide contains a tryptophan that can be liberated from the dinitrophenol (DNP) quencher by aminopeptidase activity so that the reaction can be followed by measuring tryptophan fluorescence over time. To follow hydrolysis of a short substrate, we used the dipeptide analog substrates LAMC or LpNA (leucine pnitroanilide). The initial rate versus substrate concentration profile for the long pep tide substrate followed simple MichaelisMenten kinetics (Fig. 5a) . By contrast, the dipeptide substrates showed sigmoidal velocity curves (Fig. 5b,c) , which did not follow simple MichaelisMenten kinetics (dashed curves) but were described well using an equation for multisite binding (solid curves), with apparent Hill coefficients of 2.1 and 2.3 for LAMC and LpNA, respectively. Analysis of the LAMC data required an innerfiltereffect correction term to account for the reduction in product fluorescence intensity at high substrate concentrations (see Online Methods).
We evaluated whether the ERAP1 activity was due to an oligomeric form of the enzyme, because allosteric interactions among monomeric units in an oligomeric enzyme commonly lead to sigmoidal velocity curves such as those observed for LAMC and LpNA 43 . However, dynamic lightscattering (Fig. 5d) and gelfiltration (Fig. 5e) experi ments indicated that ERAP1 is predominantly monomeric even at con centrations higher than typical enzymatic assay conditions. The peak of enzymatic activity coeluted with monomeric ERAP1 by gel filtration (Fig. 5e, bottom) . Moreover, a plot of LAMC hydrolysis activity versus ERAP1 concentration (Fig. 5f) is linear throughout the range 8.6 to 46 nM, suggesting that activity is not dependent on oligomerization in this concentration range. ERAP1 thus appears to be active as a monomer, so the substrate activation pattern observed for LAMC and LpNA is prob ably not due to allosteric interactions among subunits of an oligomeric enzyme. Instead, we explored the possibility that the interacting sites might be present as subsites within the same monomeric enzyme.
To investigate the mechanism of peptide activation of LAMC hydrolysis without potential complications from hydrolysis of the activating peptide, we used the nonhydrolyzable decapeptide L(NMe)VAFKARAF (L Me ) as an activator. The sequence of this peptide was optimized for interaction with ERAP1 based on library screening 25 , and the unmethylated version of this peptide (Lpeptide) is an excellent ERAP1 substrate and is readily processed (Fig. 6a) . In the L Me peptide, the amide group of the first peptide bond carries a methyl group that blocks catalytic cleavage, and the L Me peptide is not trimmed by ERAP1 under experimental conditions (Fig. 6b) . Increasing concentrations of both L and L Me peptides activated ERAP1's hydrolysis of LAMC (Fig. 6c,d) . A nonhydrolyzable peptide with a sequence designed for minimal ERAP1 interaction, R(NMe)VAEAAFAE, did not activate LAMC hydrolysis (data not shown). We measured initial rates of reaction in the presence of various concentrations of LAMC and L Me in order to investigate the kinetic basis of the activation mechanism. Increasing L Me concen trations resulted in a marked decrease in the sigmoidal character of the substrate velocity curve (Fig. 6e, Supplementary Fig. 3) . Kinetic analysis revealed a mixedmode activation mechanism with increas ing apparent V max and decreasing Hill coefficient with increasing L Me (Supplementary Fig. 3) . When the effect of L Me on ERAP1 enzymatic activity was evaluated using a fulllength fluor ogenic decapeptide substrate, WEVYEKC dnp ALK 42 , rather than LAMC, a concentrationdependent decrease in ERAP1 activity was observed (Fig. 6f) . L Me thus acts as an activator for hydrolysis of LAMC but as an inhibitor for the fulllength WEVYEKC dnp ALK pep tide. These results suggest that a small substrate like LAMC can bind into the catalytic site even when the regulatory subsite is occupied but a fulllength peptide substrate cannot, implying spatial proximity between the regulatory and catalytic sites.
We evaluated the proximity between regulatory and catalytic sites in an additional experiment (Fig. 4e) . Processing by ERAP1 of the LG n L series (Fig. 4b) was reevaluated in the presence of (50 µM) INFEKL, a sixresidue peptide SIINFEKL variant that is not processed appreciably by ERAP1 (Fig. 4a) but is able to activate LAMC hydroly sis (Fig. 4c) . In the presence of INFEKL, the LG n L peptide processing profile was shifted toward smaller peptides, stimulating the process ing of peptides four to six residues long and inhibiting the processing of peptides longer than ten residues (Fig. 4e) . INFEKL thus acts as an activator or an inhibitor of LG n L hydrolysis, depending on the length of the peptide substrate. Apparently, as the length of activating pep tides is increased, progressively more of the substrate binding groove becomes occupied; consequently, only shorter substrates can access and be hydrolyzed by the catalytic site. These results further support the idea that the regulatory and catalytic sites within a single binding cleft are near each other, with interaction between them dependent on the length of the substrate.
DISCUSSION
The crystal structure of ERAP1 bound to the aminopeptidase inhibitor bestatin reveals an open, fourdomain arrangement with a large solventaccessible chamber contiguous to a zincbased aminopepti dase active site. The large cavity appears to be an adaptation specific to ERAP1 and related to its ability to efficiently process peptides that are longer than the substrates of typical aminopeptidases. The ability of short peptides to allosterically activate ERAP1 toward the fluoro genic aminopeptidase substrate LAMC suggests conversion between (at least) two different forms of the enzyme dependent on peptide binding, with one more and one less active. Kinetic analysis suggests that conversion between the forms is regulated by occupancy of a regulatory subsite that is distinct from but near the enzyme active site. Comparison with a recent crystal structure of ERAP1 in a closed form suggests that the structure of ERAP1 bound to bestatin represents an open state that is not optimized for catalysis but that could adopt a more closed arrangement by simple rigidbody domain motions. The concave surface of the Cterminal helical domain ensures that after closure there would still be a cavity sufficient to accommodate a peptide substrate of as many as 13-16 residues.
A model for how subsite activation within the ERAP1 binding cleft can lead to lengthdependent cleavage of peptide substrates is shown in Figure 7 . In this model, binding to a regulatory site promotes a conformational change to a closed conformation with increased enzymatic activity. Short peptide substrates cannot reach from the catalytic site to the regulatory site (Fig. 7a) , so are not able to sta bilize the closed conformation. As a result, they will be processed at a slower rate. Peptides longer than about eight or nine residues can concurrently occupy the catalytic and regulatory sites (Fig. 7b) , leading to the stabilization of the closed, active conformation and efficient trimming. Short fluorogenic substrates cannot reach from the catalytic site to the regulatory site (Fig. 7c) and are processed inef ficiently, unless catalysis is accelerated by occupancy of the regulatory site (Fig. 7d) . The regulatory site can be occupied by the fluorogenic substrate itself if the substrate is present at high concentration, lead ing to positive cooperativity and sigmoidal activation kinetics, or by binding of an activator peptide, provided that the peptide does not interfere sterically with substrate binding. For a fulllength substrate that occupies both catalytic and regulatory sites, no cooperativity and hyperbolic (MichaelisMenten) kinetics are observed. Similarly, a nonhydrolyzable peptide activator of LAMC kinetics acts as an inhibitor for hydrolysis of a fulllength peptide, because in this case, occupancy of the regulatory site prevents substrate binding. This model explains the efficiency of ERAP1 in trimming long substrates, because such substrates can activate their own trimming by binding to both the regulatory and catalytic sites. Furthermore, this model can explain the slow trimming rate for small substrates that are too short to selfactivate the enzyme. Occupancy of both catalytic and regula tory sites within the overall extended peptide binding site is thus an important determinant for efficient trimming. Similar subsite activa tion models have been proposed to explain the length preference of bovine RNase A 44 and the sigmoidal velocity plots observed for the monomeric Bacillus subtilis phosphatidylinositolspecific phospholi pase C when assayed with shortchain lipid analog substrates 45 . The location of the regulatory site(s) within the ERAP1 structure is not yet clear in the absence of structural data for a bound peptide complex, but one possible site might be the inner surface of the top of helices H20 and H22, which in the closed conformation would contact an extended version of the tripeptide model shown in Figure 3 , influ encing interactions between helix H22 and helix H5 near the active a r t i c l e s site (see below). Overall, this model is consistent with the biological role of ERAP1 in efficiently removing one to seven residues from the N terminus of antigenic peptide precursors with broad specificity but sparing many mature antigenic peptides.
How could conversion between open and closed conformations regulate ERAP1's enzymatic activity? The arrangement of key func tional groups in the active site of ERAP1 is identical to that observed for other M1family members, except for Tyr438, which is oriented away from the catalytic zinc in ERAP1 but toward it in most other M1 aminopeptidase structures (Fig. 2c) . The one other exception is TIFF3, which like ERAP1 is in an open conformation 46 and which also has the Tyr438 analog also oriented away from the active site 32 . In the closed form of ERAP1, a small ~30-40° rotation of helix H5 orients Tyr438 toward the active site, in a position to participate in peptide bond hydrolysis chemistry. Helix H5 is oriented toward the Cterminal domain, sandwiched between helix H3, which carries the second glutamate of the HExxHx 18 E motif, and helix H4, which packs against helix H10 of the Cterminal domain. In the open conformation, no direct contacts between helix H5 and the Cterminal domain are observed, although a disordered region for which we do not observe electron density extends from the end of helix 5 toward the Cterminal domain. Two other disordered regions are found directly across the cavity, between the tops of helices H21 and H22, and between the tops of helices H23 and H24 (Fig. 1c) . In the closed conformation, these regions make contact with the disordered region upstream of helix H5, folding and packing against the loops between helices H21 and H22 and between H23 and H24. This interaction appears to result in reorientation of helix H5, motion of Tyr438 and capping of the S1 site, all changes which would favor increased catalytic activity.
Structural studies of other enzymes related to ERAP1 suggest that domain motions triggered by peptide binding could induce active site changes to enhance peptidase activity as suggested here. In two multi domain zinc metallopeptidases distantly related to ERAP1, human angiotensinconverting enzymerelated carboxypeptidase (ACE2) 47 and Escherichia coli dipeptidyl carboxypeptidase (Dcp) 48 , domain closure motions have been associated with activesite reorganizations favoring catalysis. In two singledomain zinc metallopeptidases more closely related to ERAP1, thermolysin 49 and astacin 50 , subdomain motions similarly reorient active site residues for hydrolysis.
The open conformation of ERAP1 may be important for cataly sis because it can facilitate long substrate approach and capture. Lowaffinity, lowspecificity binding sites on the interior surface of the cavity, similar to those present on nuclear importinα, another armadillo and HEAT repeat protein 51 , might enable efficient peptide capture in the open form. Cavity closure could help to align peptides toward the active site for Nterminal processing, and differential expo sure of interior binding sites between open and closed forms could facilitate peptide binding and release cycles, which would appear to be necessary for sequential removal of peptide N termini as a long antigenic precursor is processed. This type of mechanism has been suggested for insulindegrading enzyme, a dimeric chambered zinc endopeptidase with 'exosites' for binding entrapped peptide at posi tions distant from the hydrolytic site 52, 53 . Recently, ERAP1's paralog IRAP has been shown to process relatively long peptides 54 . If this model is correct, then IRAP also would be expected to adopt open and closed conformations during catalysis.
Based on the ERAP1 crystal structures, length and sequence spe cificity, allosteric regulation by peptides and comparison with other M1family proteases, we can describe a probable mechanism for ERAP1 processing of antigenic precursors. (i) Antigenic precursor peptides can access and bind to the groove while the protein is in an open conformation, using interactions at Nterminal S1 and S1′ sites but also interactions at other sites in the cavity. Active site residues are not in the optimal arrangement. Figure 8 shows sites of eight singlenucleotide polymorphisms that are present in allelic variants of ERAP1 associated with altered risk of developing anky losing spondylitis 55, 56 . Potential effects of some of these variants can be identified by examination of the structure of ERAP1. M349V is located in the active site and R725Q and Q730E are exposed on the inner surface of the Cterminal cavity that could affect substrate sequence or length specificity. Other polymorphisms-R127P, K528R, D575N and V647I-at domain junctions could indirectly affect spe cificity or enzymatic activity by altering the conformational change between open and closed forms. Altered peptide trimming by ERAP1 variants may lead to altered levels of arthritogenic self peptides or of their mimics, or may lead to altered generation of Tcell clones in the thymus. Structureguided studies of the specificity and activity of these ERAP1 variants are clearly warranted.
The crystal structure of ERAP1 bound to bestatin provides insight into ERAP1's unusual length specificity and its peptide sequence preferences. These intrinsic properties of ERAP1 with MHCbinding protection contribute to the length and sequence distribution of MHC class I bound antigens. It appears that both the overall conforma tion of ERAP1 as well as its ability to be activated by long substrates are features that the enzyme has evolved in order to trim large anti genic precursor peptides while sparing peptides of length suitable for MHC binding. 
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